☆ 4.6 Editorial Material

Is the Harm-to-Benefit Ratio a Key Criterion in Vaccine Approval?

FRONTIERS IN MEDICINE (2022)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021

Matthew E. Oster et al.

Summary: Based on reports in the US, the risk of myocarditis after receiving mRNA-based COVID-19 vaccines was increased, especially among adolescent males and young men, particularly after the second dose. This risk should be considered in the context of the benefits of COVID-19 vaccination.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Article Infectious Diseases

Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study

Anika Singanayagam et al.

Summary: Vaccination reduces the risk of delta variant infection and accelerates viral clearance. However, fully vaccinated individuals with breakthrough infections may still have similar peak viral loads as unvaccinated cases and can efficiently transmit the infection.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov et al.

Summary: The Gam-COVID-Vac vaccine showed 91.6% efficacy against COVID-19 in the phase 3 trial, with good safety and tolerability in a large cohort of participants.

LANCET (2021)

Add to Collection

Is the Harm-to-Benefit Ratio a Key Criterion in Vaccine Approval?

Related references

Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021

Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Export Citation

Share Paper